ArticleAnnals of surgery2026
Long-term (>5 Years) Outcomes after Magnetic Sphincter Augmentation.
Article in Annals of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo report the long-term (5 years) patient-reported outcomes and objective pH measurements of patients undergoing magnetic sphincter augmentation (MSA).
backgroundMSA controls gastroesophageal reflux disease (GERD) as demonstrated in multiple studies. Consistent patient-reported outcomes and objective data support its use in short-term follow-up. Long-term data are required.
methodsThis FDA post-approval study enrolled patients from 2013 to 2015, with confirmed GERD despite acid suppression therapy, undergoing laparoscopic implantation of a magnetic sphincter with a minimum of 5 years of follow-up were included. Clinical success was defined as a ≥50% improvement in the total GERD-health-related quality of life score compared with the baseline off proton pump inhibitors (PPIs). Secondary outcomes were objective evidence of GERD control on pH testing and the use of PPIs.
resultsA total of 136/200 patients were available for follow-up. A ≥50% improvement in the GERD-health-related quality of life score was achieved in 81.6% with the median score improving from 26 to 4. Freedom from daily PPI use was 90.4%. Objectively, the % time pH <4 went from 9.1 to 3.2, and the DeMeester score from 29 to 11 in 81 patients. The ability to belch and vomit was retained if needed. Dysphagia occurred in 5%. There were 27 (13%) devices explanted with only 4 (2%) erosions. Of these, 25 (92.6%) patients had resolution of their symptoms with removal, conversion to fundoplication, or replacement of the device.
conclusionsMSA controls symptoms of GERD without the need for PPIs but may need explantation in 13% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.